Navigation Links
Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
Date:9/23/2008

AURORA, Ontario, Sept. 23 /PRNewswire/ -- Helix BioPharma announced today that Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., will be presenting L-DOS47 research findings at the National Research Council of Canada's (NRC) Eighth Annual General Meeting of the Genomics and Health Initiative, today in Saskatoon, Saskatchewan, Canada. The meeting includes Canadian researchers from across the NRC, government departments and private industry and covers diverse topics in genomics research.

Dr. Chao's presentation, titled "L-DOS47: Targeting the Tumor Microenvironment with an Immunoconjugate" will provide a summary of selected previously announced L-DOS47 research findings. "We are very pleased to have been invited to participate in this important scientific forum," said Dr. Chao. "It is an excellent opportunity to showcase our findings to Canada's research community as we continue to advance our L-DOS47 development program.

For additional information on the Genomics and Health Initiative conference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm .

About L-DOS47

L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimul
'/>"/>

SOURCE Helix BioPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... (Nasdaq and SWX: BMRN) announced today the appointment,of ... Former Vice President of,Research and Development for Raven ... patents and the recipient of a,collection of prestigious ... Awards from Intellectual Property Owners, Inc., "We ...
... Therapeutics Inc., an,early stage biotechnology company developing therapies ... Drug application (IND),to the U.S. Food and Drug ... the first-in-man clinical trials for its lead compound,VEL-0230., ... has dual-acting properties, in,that it both stimulates bone ...
... N.J., Jan. 28 Ferring Pharmaceuticals Inc.,has announced ... will serve as the title sponsor of the ... GeezerJock of the Year,Award., "This is such ... for,senior athletes," said Alex Drigan, Product Manager, EUFLEXXA(TM). ...
Cached Biology Technology:BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 2BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 3Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Rehabilitation Medicine at NYU Langone Medical Center will ... rehabilitation, the treatment of traumatic brain injuries and ... at the American Association of Physical Medicine and ... 2011. Experts will be available to comment about ...
... (University of Turku and VTT Technical Research Centre of Finland) ... Institute for Health and Welfare) have discovered that the SHARPIN ... leading journal, the study concludes that SHARPIN regulates the movement ... cancer cells. It is likely that the discovery will also ...
... Palo Alto, CAU.S. scientists have developed a new, integrated, ... carbon cycle and people,s role in it. Understanding the carbon ... sustainable future. The plan builds on the first such plan, ... the role of humans as agents and managers of carbon ...
Cached Biology News:Rusk experts present at American Association of Physical Medicine and Rehabilitation meeting 2Scientists tackle the carbon conundrum 2
Request Info...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: